Other lysosomal exoglycosidase activity, i.e., α-fucosidase (FUC), β-galactosidase (GAL), α-mannosidase (MAN), and β-glucuronidase (GLU), have been evaluated in numerous physiopathological situations such as hepatocellular carcinoma (HCC), liver disease, and gastric tumors, alcohol dependence, and colon and larynx cancers [17–22], but not in kidney diseases in children. This evidence concerns the gene GAL and kidney disorder.